Correction to: Nature Communications 10.1038/s41467-023-40061-y, published online 24 July 2023
In this article the author name R. C. Coombes was incorrectly written as R. Charles Coombes. The original article has been corrected.
. 2023 Aug 7;14:4741. doi: 10.1038/s41467-023-40561-x
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
R C Coombes
1, Sacha Howell
2, Simon R Lord
3, Laura Kenny
1, Janine Mansi
4, Zahi Mitri
5, Carlo Palmieri
6, Linnea I Chap
7, Paul Richards
8, William Gradishar
9, Sagar Sardesai
10, Jason Melear
11, Joyce O’Shaughnessy
11, Patrick Ward
10, Pavani Chalasani
12, Tobias Arkenau
13, Richard D Baird
14, Rinath Jeselsohn
15, Simak Ali
1, Glen Clack
16, Ashwani Bahl
16, Stuart McIntosh
16, Matthew G Krebs
2,✉
Sacha Howell
2Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Find articles by Sacha Howell
Simon R Lord
3Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK
Find articles by Simon R Lord
Jason Melear
11Baylor University Medical Center, Texas Oncology, Dallas, TX USA
Find articles by Jason Melear
Joyce O’Shaughnessy
11Baylor University Medical Center, Texas Oncology, Dallas, TX USA
Find articles by Joyce O’Shaughnessy
Pavani Chalasani
12University of Arizona Cancer Center, Tucson, AZ USA
Find articles by Pavani Chalasani
Richard D Baird
14Cancer Research UK Cambridge Centre, Cambridge, UK
Find articles by Richard D Baird
Matthew G Krebs
2Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Find articles by Matthew G Krebs
1Imperial College, South Kensington, London, UK
2Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
3Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK
4Guy’s and St Thomas’ NHS Foundation Trust, London, UK
5OHSU Knight Cancer Institute, Portland, OR USA
6University of Liverpool, Liverpool, UK
7University of California, Los Angeles, CA USA
8Blue Ridge Cancer Center, Salem, VA USA
9Northwestern University, Chicago, IL USA
10US Oncology Research, OHC, Cincinnati, OH USA
11Baylor University Medical Center, Texas Oncology, Dallas, TX USA
12University of Arizona Cancer Center, Tucson, AZ USA
13Sarah Cannon Research Institute, London, UK
14Cancer Research UK Cambridge Centre, Cambridge, UK
15Dana-Farber Cancer Institute, Boston, MA USA
16Carrick Therapeutics, Dublin, Ireland
✉
Corresponding author.
Collection date 2023.
Subject terms: Breast cancer, Drug development, Drug development
© The Author(s) 2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
PMCID: PMC10406871 PMID: 37550302
This corrects the article "Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib", 4444.